Researchers at MIT reported a new lipid nanoparticle (LNP) formulation that delivered an influenza mRNA vaccine at roughly 1/100th the dose of current FDA‑approved LNP materials while achieving equivalent immune responses in mouse models. The team used degradable cyclic amino ionizable lipids (AMG1541 among candidates) developed through combinatorial chemistry and in vivo screening to improve endosomal escape and biodegradability. The study, published in Nature Nanotechnology, details rational design and screening steps that identified ionizable lipids with cyclic structures and ester linkages to enhance potency and clearance. Lower effective doses could reduce per‑dose cost, manufacturing burdens, and reactogenicity for mRNA vaccines and therapeutics. If translated to humans, the platform may enable broader, lower‑cost vaccine campaigns and improve tolerability for repeat dosing modalities. Developers and manufacturers will need translational safety data, scale‑up demonstrations, and regulatory engagement to move such LNP chemistries into clinical testing.